-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

Benzinga·10/15/2026 10:38:01
Diffusion vocale
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.